Currently, only adalimumab is approved by the United States Food and Drug Administration (FDA) for the treatment of hidradenitis suppurativa.
, Approval FDA Approves Novartis' Cosentyx as the First New Biologic Treatment Option for Hidradenitis Suppurativa Patients in
COSENTYX (secukinumab) is the first FDA-approved medicine of its kind to treat adults with moderate to severe hidradenitis suppurativa (HS).
The FDA has approved Cosentyx for the treatment of adults with moderate to severe hidradenitis suppurativa, Novartis announced in a press release.
Hidradenitis suppurativa on four different skin colors. Hidradenitis suppurativa Enlarge image Clindamycin (topical): Drug information. https
, Janu]In late October 2024, the FDA granted approval to Novartis' Cosentyx (secukinumab) for treating hidradenitis suppurativa (
ABRILADA is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. FDA-approved patient labeling (Medication Guide and
COSENTYX (secukinumab) is the first FDA-approved medicine of its kind to treat adults with moderate to severe hidradenitis suppurativa (HS). Hidradenitis suppurativa (HS) is a chronic, or long-lasting, inflammatory skin condition.
Currently, HUMIRA (adalimumab) and COSENTYX (secukinumab) are the only biologics approved by the US FDA for treating hidradenitis suppurativa. BIMZELX (
The problem is home pregnancy tests were not approved by the FDA until 1976 and did not arrive on the market until 1978.